Fiche société
Hrain Biotechnology Co., Ltd.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Human CD19 targeted T Cells InjectionTo evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive diffuse large B-cell lymphoma and follicular lymphoma. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells. | SEP | Phase 1 | Immunomodulation | China | À vérifier |
| Human CD19 targeted T Cells InjectionTo evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive diffuse large B-cell lymphoma and follicular lymphoma. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells. | SEP | Phase 1 | Thérapie cellulaire + Immunomodulation | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Human CD19 targeted T Cells Injection | SEP | Phase 1 | NCT03720457 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | UNKNOWN |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Human CD19 targeted T Cells Injection | Human single domain antibody-based CAR-T cells targeting BAFF-R demonstrate promising preclinical activity in B-cell malignancies. | BMC cancer | ||
| Human CD19 targeted T Cells Injection | Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy. | Haematologica |